RT Journal Article
SR Electronic
T1 Carrier frequency estimation of pathogenic variants of autosomal recessive and X-linked recessive Mendelian disorders using exome sequencing data in 1,642 Thais
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.06.12.23291300
DO 10.1101/2023.06.12.23291300
A1 Chetruengchai, Wanna
A1 Phowthongkum, Prasit
A1 Shotelersuk, Vorasuk
YR 2023
UL http://medrxiv.org/content/early/2023/06/20/2023.06.12.23291300.abstract
AB People with autosomal recessive disorders often were born without awareness of the carrier status of their parents. The American College of Medical Genetics and Genomics (ACMG) recommends screening 113 genes known to cause autosomal recessive and X-linked conditions in couples seeking to learn about their risk of having children with these disorders to have an appropriate reproductive plan. Here, we analyzed the exome sequencing data of 1,642 unrelated Thai individuals to identify the pathogenic variant (PV) frequencies in genes recommended by ACMG. The ascertainment bias was controlled by excluding the carriers of the PV in the genes for the conditions that are attributed to their offspring disorders. In the 113 ACMG-recommended genes, 165 PV and likely PVs in 60 genes of 559 exomes (34%, 559/1642) were identified. The carrier rate was increased to 39% when glucose-6-phosphate dehydrogenase (G6PD) was added. The carrier rate was still as high as 14.7% when thalassemia and hemoglobinopathies were excluded. In addition to thalassemia, hemoglobinopathies, and G6PD deficiency, carrier frequencies of >1% were found for Gaucher disease, primary hyperoxaluria, Pendred syndrome, and Wilson disease. Nearly 2% of the couples were at risk of having offsprings with the tested autosomal recessive conditions. The expanded carrier screening focused on common autosomal recessive conditions in Thai seems to be benefit among the study samples.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNO- The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscriptAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board of the Faculty of Medicine, Chulalongkorn University (IRB No. 264/62).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll relevant data are within the manuscript and its Supporting Information files